Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

832
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
832
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

800
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
800
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

963
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
963
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

658
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
658
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

322
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
322

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A comparison of the safety of oral labetalol versus nifedipine to manage hypertension in pregnancy in Australia: a target trial emulation.

EClinicalMedicine·2026
Same author

Identifying novel prodromal symptoms of eclampsia: A two-country, case-control study.

PLoS medicine·2026
Same author

Impaired Hearing and Systolic Blood Pressure as Potential Markers of Cerebral Infarction After Eclampsia: A Cross-Sectional Study.

BJOG : an international journal of obstetrics and gynaecology·2026
Same author

Safety and pharmacokinetics of sulfasalazine and its metabolite sulfapyridine for treatment of preterm preeclampsia in Australia (SIP): an early phase, unblinded, single-arm, proof of concept clinical trial.

EClinicalMedicine·2026
Same author

Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial.

BMJ open·2025
Same author

Reducing term pre-eclampsia by 30%: is it possible?

Lancet (London, England)·2025
Same journal

Study confirms benefits of continuous glucose monitoring in type 2 diabetes.

Drug and therapeutics bulletin·2026
Same journal

Update on spasticity: part-2 - physical, pharmacological and surgical management.

Drug and therapeutics bulletin·2026
Same journal

Reducing thrombosis risk much earlier in pregnancy: the new NHS Maternal Care Bundle.

Drug and therapeutics bulletin·2026
Same journal

Once-weekly insulin (insulin efsitora) for patients with type 2 diabetes.

Drug and therapeutics bulletin·2026
Same journal

Optimising treatment options in scabies.

Drug and therapeutics bulletin·2026
Same journal

Dupilumab in chronic obstructive pulmonary disease.

Drug and therapeutics bulletin·2026
See all related articles

Related Experiment Video

Updated: Nov 15, 2025

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
12:02

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Published on: July 30, 2016

16.2K

Aspirin to prevent pre-eclampsia.

Stephen Tong1,2, Susan Walker3,2, Catherine Cluver2,4

  • 1Translational Obstetrics Group, Department of Obstetrics and Gynaecology, University of Melbourne, Heidelberg, Victoria, Australia stong@unimelb.edu.au.

Drug and Therapeutics Bulletin
|March 4, 2021
PubMed
Summary
This summary is machine-generated.

Drug and Therapeutics Bulletin (DTB) provides concise reviews of treatments to ensure optimal patient care. Articles offer key summaries and patient overviews, with optional continuing medical education (CME) questions.

Keywords:
blood pressurepharmacypregnancyprimary health care

More Related Videos

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

1.1K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.5K

Related Experiment Videos

Last Updated: Nov 15, 2025

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
12:02

Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption

Published on: July 30, 2016

16.2K
Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

1.1K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.5K

Area of Science:

  • Clinical Pharmacy
  • Evidence-Based Medicine

Background:

  • Drug and Therapeutics Bulletin (DTB) is a trusted source for unbiased drug information.
  • The editorial board selects topics to address current clinical needs and patient care.

Purpose of the Study:

  • To provide concise and accessible overviews of medicines and treatments.
  • To support healthcare professionals in delivering optimal patient care.
  • To enhance medical knowledge through review articles and CME opportunities.

Main Methods:

  • Selection of review topics by the DTB editorial board.
  • Development of articles including key points and patient-friendly summaries.
  • Inclusion of multiple-choice questions for continuing medical education (CME).

Main Results:

  • DTB articles offer clear summaries of complex medical information.
  • Patient overviews facilitate better understanding and adherence.
  • CME questions reinforce learning and professional development.

Conclusions:

  • DTB serves as a valuable resource for healthcare providers seeking up-to-date treatment information.
  • The format supports both professional learning and patient education.
  • Regular reviews ensure the dissemination of evidence-based therapeutic guidance.